brain, this is what this drug does, starts to get removed really significantly. but that patient on the bottom, you can see those yellow areas of the brain are still really present. that is showing that they have these plaque buildups that stay there and this is contributing to the course of alzheimer s disease. what this study showed is by successfully removing that plaque, you can slow the course of the disease in this case by 35% on average. there has been so much hope and so much disappointment in really well-known alzheimer s drugs. and the expense there have been big fights in government over the expense of these drugs for older patients. how much do we have any sense of how much of a cost? would it be covered by medicare, medicaid? that is the key question. right now, there is a drug approved, but it is not covered broadly by medicare. and of course, this is a population that requires medicare coverage. that drug costs more than $26,000 a year. we don t yet know where li
Takeda s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
How Exercise May Help Keep Our Memory Sharp
nytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nytimes.com Daily Mail and Mail on Sunday newspapers.
Seeking Early Signals of Dementia in Driving and Credit Scores
nytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nytimes.com Daily Mail and Mail on Sunday newspapers.